2. NF-κB PI3K/Akt/mTOR TGF-beta/Smad Stem Cell/Wnt
  3. NF-κB PI3K Akt TGF-beta/Smad
  4. Micheliolide

Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis.

For research use only. We do not sell to patients.

CAS No. : 68370-47-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Micheliolide:

Micheliolide Related Antibodies

Top Publications Citing Use of Products

    Micheliolide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2026 Feb 21;24(1):431.

    Western blot and quantitative analysis of EMT-related markers in the capsular bags after ECLE combined with injection of saline or Micheliolide (MCL) (5 mM) into the anterior chamber.

    Micheliolide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2026 Feb 21;24(1):431.

    qRT-PCR analysis of α-SMA, Col I, and FN in capsular bags after ECLE with or without anterior chamber injection of Micheliolide (MCL) (5 mM).

    Micheliolide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2026 Feb 21;24(1):431.

    Representative HE staining shows cell proliferation and migration in the capsular bags following treatment with ECLE co-treated with an anterior chamber injection of saline or Micheliolide (MCL) (5 mM).

    Micheliolide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2026 Feb 21;24(1):431.

    Viability test of LECs at gradient concentrations of Micheliolide (MCL) (1.25, 2.5, 5, 10, 20 μM).

    Micheliolide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2026 Feb 21;24(1):431.

    Representative images of the scratch wound assay in LECs at 0, 24, and 48 hours. Cells were pretreated with or without 5 μmol/L Micheliolide (MCL) and then stimulated with 10 ng/mL TGF-β2.

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    View All PI3K Isoform Specific Products:

    View All Isoforms
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis[1][2][3][4].

    Cellular Effect
    Cell Line Type Value Description References
    HL-60 IC50
    5.5 μM
    Compound: 9, MCL
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    		[PMID: 22985027]
    In Vitro

    Micheliolide (0.2-10 μM, 24 h) decreases the proliferation of mesangial cells and the production of MCP-1, TGF-β1, FN increased by a high concentration of glucose (HG) and suppresses the HG-induced degradation of IκBα[1].
    Micheliolide (1-10 μM, 18 h) does not affect the growth and apoptosis of Raw264.7. I[2].
    Micheliolide (1-10 μM, 3-18 h) inhibits LPS-triggered inflammatory responses in mouse macrophages, dendritic cells (DCs), human monocytic cell line THP-1, human CD14+ monocytes and inhibits LPS-induced NF-κB and PI3K/Akt/p70S6K activation[2][3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Micheliolide Related Antibodies

    Real Time qPCR[2]

    Cell Line: Mouse macrophages and dendritic cells
    Concentration: 1-10 μM
    Incubation Time: 3-18 h
    Result: Inhibited LPS-induced IL-6, TNF-α, IL-1β, MCP-1, IFN-β and IL-10 production in Raw264.7 and mouse primary peritoneal macrophages.

    Western Blot Analysis[2]

    Cell Line: Raw264.7 cells
    Concentration: 10 μM
    Incubation Time: 0-180 min
    Result: Inhibited LPS-induced phosphorylation of IκBα (Ser32/36) in Raw264.7.
    In Vivo

    Micheliolide (10 or 20 mg/kg, i.p., a single dose for 2 h) attenuates the secretion of serum cytokines and protects against lung and liver tissue damage in LPS (10mg/kg, i.p., a single dose for 2 h)-challenged mice[2].
    Micheliolide (10 or 20 mg/kg, i.p., a single dose for 6 days) enhances the survival rate in mice following lethal septic shock[2].
    Micheliolide (30 mg/kg, i.p., every two days for 63 days) reduces swelling of the paws and suppresses the degeneration of articular cartilage in collagen-induced arthritis mice[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Acute peritonitis mouse model[2]
    Dosage: 10 or 20 mg/kg
    Administration: i.p., a single dose for 2 h
    Result: Suppressed LPS-induced production of proinflammatory cytokines, chemokines and IFN in macrophages and DCs, showing clearer alveolar wall and less inflammatory cell infiltration.
    Animal Model: Septic shock mouse model[2]
    Dosage: 10 or 20 mg/kg
    Administration: i.p., a single dose for 6 days
    Result: Protected mice against septic shock following lethal LPS challenge.
    Animal Model: Collagen-induced arthritis mice[4]
    Dosage: 30 mg/kg
    Administration: i.p., every two days for 63 days
    Result: Remited the pathological changes of collagen-induced arthritis and recovered the expression levels of M-CSF, TIMP-1 and C5/C5a in collagen-induced arthritis mice.
    Molecular Weight

    248.32

    Formula

    C15H20O3
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O[C@@]1([H])[C@@]2([H])CCC(C)=C3CC[C@@](C)(O)[C@@]31[H])C2=C
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (201.35 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0271 mL 20.1353 mL 40.2706 mL
    5 mM 0.8054 mL 4.0271 mL 8.0541 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.77%

    SDS (393 KB)

    COA (260 KB) HNMR (270 KB) LCMS (90 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.0271 mL 20.1353 mL 40.2706 mL 100.6765 mL
    5 mM 0.8054 mL 4.0271 mL 8.0541 mL 20.1353 mL
    10 mM 0.4027 mL 2.0135 mL 4.0271 mL 10.0677 mL
    15 mM 0.2685 mL 1.3424 mL 2.6847 mL 6.7118 mL
    20 mM 0.2014 mL 1.0068 mL 2.0135 mL 5.0338 mL
    25 mM 0.1611 mL 0.8054 mL 1.6108 mL 4.0271 mL
    30 mM 0.1342 mL 0.6712 mL 1.3424 mL 3.3559 mL
    40 mM 0.1007 mL 0.5034 mL 1.0068 mL 2.5169 mL
    50 mM 0.0805 mL 0.4027 mL 0.8054 mL 2.0135 mL
    60 mM 0.0671 mL 0.3356 mL 0.6712 mL 1.6779 mL
    80 mM 0.0503 mL 0.2517 mL 0.5034 mL 1.2585 mL
    100 mM 0.0403 mL 0.2014 mL 0.4027 mL 1.0068 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Micheliolide Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Micheliolide68370-47-8NF-κBPI3KAktTGF-beta/SmadNuclear factor-κBNuclear factor-kappaBPhosphoinositide 3-kinasePKBProtein kinase BTransforming growth factor betasesquiterpene lactoneanti-canceranti-inflammatoryIκBαMCP-1TGF-β1FNmouse mesangial cellsinflammatory intestinal diseasecolitis-associated cancerrheumatic arthritisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Micheliolide
    Cat. No.:
    HY-N0847
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.